IceCure's ProSense® Shows 83.9% Four-Year Recurrence-Free Rate, 89.4% in Small Tumors
At a median four-year follow-up of 112 evaluable ICESECRET trial patients, ProSense® achieved an 83.9% recurrence-free rate, rising to 89.4% in tumors ≤3 cm with no prior kidney cancer. These results support broader commercial adoption as a minimally invasive cryoablation option in approved U.S. and European markets.
1. ICESECRET Trial Outcomes
The ICESECRET study enrolled 114 kidney cancer patients, with 112 evaluable at a median follow-up of four years. The overall recurrence-free rate reached 83.9%, with 12 patients undergoing a second cryoablation at an average of 1.73 years post-procedure.
2. Subgroup Efficacy in Small Tumors
In the subset of patients with tumors ≤3 cm, no prior kidney cancer history and successful initial procedures, ProSense® delivered an 89.4% recurrence-free rate, highlighting its effectiveness in treating small renal masses.
3. Commercial Expansion Potential
These durable long-term results bolster ProSense®’s value proposition as a minimally invasive alternative to surgery, supporting plans for broader commercial adoption across U.S. and European markets where the system is already approved.